Replies to post #4953 on Blueone Card Inc. (BCRD)

[elbiatcho1]

Domain Name: EBOLA-C.COM
Registry Domain ID: 1878475737_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Update Date: 2014-10-01 10:59:50
Creation Date: 2014-10-01 10:59:50
Registrar Registration Expiration Date: 2015-10-01 10:59:50
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: mailto:[e-mail]
Registrar Abuse Contact Phone: [phone]
Domain Status: clientTransferProhibited
Domain Status: clientUpdateProhibited
Domain Status: clientRenewProhibited
Domain Status: clientDeleteProhibited
Registry Registrant ID:
Registrant Name: Todd Spinelli
Registrant Organization:
Registrant Street: 11735 Colony Lakes Blvd
Registrant City: fairbanks
Registrant State/Province: Alaska
Registrant Postal Code: 99701
Registrant Country: United States
Registrant Phone: [phone]
Registrant Phone Ext:
Registrant Fax:
Registrant Fax Ext:
Registrant Email: mailto:[e-mail]

[elbiatcho1]

FDA Warning against EBOLA-C.com

http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2014/ucm423685.htm

TO: Todd Spinelli
[e-mail]
[e-mail]
www.ebola-c.com

FROM: The Food and Drug Administration and the Federal Trade Commission

RE: Unapproved Products Related to Ebola and Notice of Potential Illegal Marketing of Products to Prevent, Treat or Cure Ebola Virus



WARNING LETTER


This is to advise you that in October 2014 the U.S. Food and Drug Administration (FDA) and the United States Federal Trade Commission (FTC) reviewed your website at http://www.ebola-c.com from which you take orders for your product, “Ebola-C®.” We also note that the website at http://www.ebolac.com automatically re-directs consumers to http://www.ebola-c.com. Based on FDA’s review, we have determined that your website promotes your product for conditions that cause the product to be a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)]. The therapeutic claims on your website establish that the product is a drug because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act....